title: Differential expression of platelet-derived endothelial cell growth factor (thymidine phosphorylase) in nonpolypoid and polypoid lesions of the colon.
abstract: To clarify the relationship between angiogenesis and the early development of colon cancer, expression of platelet-derived endothelial cell growth factor (PD-ECGF), a known angiogenic and endothelial cell chemotactic factor, was examined in 119 human colon premalignant adenomas and colon carcinomas. Localization of PD-ECGF was assessed by immunocytochemistry in 70 nonpolypoid growth (NPG) lesions that represented 29 carcinomas (NPG carcinomas) and 41 adenomas (NPG adenomas) and 49 polypoid growth (PC) lesions that included 15 carcinomas (PG carcinomas) and 34 adenomas (PC adenomas). Simultaneously, the expression of tranforming growth factor alpha (TGF alpha) and epidermal growth factor receptor (EGFR) were examined in serial sections from these lesions. Twenty (68.9%) of 29 NPC carcinomas and 20 (48.7%) of 41 NPC adenomas exhibited positive staining for PD-ECGF, whereas 15 (100%) of 15 PG carcinomas and 27 (79.4%) of 34 PG adenomas expressed PD-ECGF. There was a statistically significant difference in the frequency of PD-ECGF expression between NPG adenomas and PG adenomas (p<0.01). In addition, the incidence of PD-ECGF expression was higher in PG carcinomas than in NPG carcinomas (p<0.05). Positive staining for TGF alpha and EGFR was detected in 14 (48.2%) and 10 (34.5%) of 29 NPG carcinomas, respectively, whereas, 17 (41.5%) and 13 (31.7%) of 41 NPG adenomas expressed TGF alpha and EGFR, respectively. A significant trend for coexpression of PD-ECGF and TGF alpha was detected in either NPG adenomas (p<0.05) or PG adenomas (p<0.01). These data demonstrate that PD-ECGF may be involved in the early stages of colon cancer development during the adenoma-carcinoma transition and additionally that angiogenesis which may be induced by PD-ECGF and/or TGF alpha could play an important role of colon cancer development.
authors.affiliation: NATL SHIKOKU CANC CTR HOSP,DEPT SURG,MATSUYAMA,EHIME 790,JAPAN. GUNMA CANC CTR,MAEBASHI,GUMMA,JAPAN. UNIV TOKYO,DEPT SURG,TOKYO,JAPAN. NATL CANC INST,NIH,TUMOR GROWTH FACTOR SECT,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD. NIPPON ROCHE RES CTR,DEPT ONCOL,KAMAKURA,KANAGAWA 247,JAPAN. NATL SHIKOKU CANC CTR HOSP,DEPT PATHOL,MATSUYAMA,EHIME 790,JAPAN. NATL SHIKOKU CANC CTR HOSP,DEPT INTERNAL MED,MATSUYAMA,EHIME 790,JAPAN.
authors.forename: T
authors.initials: T
authors.lastname: Saeki
authors.forename: S
authors.initials: S
authors.lastname: Takashima
authors.forename: S
authors.initials: S
authors.lastname: Hosokawa
authors.forename: S
authors.initials: S
authors.lastname: Moriwaki
authors.forename: K
authors.initials: K
authors.lastname: Nagasako
authors.forename: T
authors.initials: T
authors.lastname: Masaki
authors.forename: D
authors.initials: D
authors.lastname: Salomon
authors.forename: H
authors.initials: H
authors.lastname: Ishitsuka